Katie Gordon

Prior to joining Harvard's Office of Technology Development in 2004, Dr. Gorgon served as a consultant to several early-stage biomedical companies in the areas of strategic development and operations/management.
She previously founded and ran biotechnology company Apollo BioPharmaceutics, a neuroscience company that developed novel neuroprotective compounds for Alzheimer's disease and ophthalmic indications and was by acquired by MitoKor Corp.
Prior to Apollo/MitoKor, she was a Director at Genzyme Corporation.
Dr. Gordon was a post-doctoral fellow at Yale University and holds a PhD from Wesleyan University.